GSK steps in for J&J’s license of Arrowhead’s hepatitis B drug, plans combo study with its own candidate

British drug­mak­er GSK plans to ac­quire an ex­per­i­men­tal he­pati­tis B drug from John­son & John­son and its de­vel­op­er Ar­row­head Phar­ma­ceu­ti­cals and then com­bine the siR­NA with its own late-stage ther­a­py to de­vel­op an even more ef­fec­tive po­ten­tial treat­ment.

Per the deal, an­nounced Tues­day morn­ing, GSK will pay less than $100 mil­lion up­front to J&J and Ar­row­head for glob­al rights to de­vel­op and mar­ket JNJ-3989, a source fa­mil­iar with the mat­ter told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.